Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B‑cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184.

Article  PubMed  PubMed Central  Google Scholar 

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.

Article  PubMed  CAS  Google Scholar 

Isidori A, Piccaluga PP, Loscocco F, Guiducci B, Barulli S, Ricciardi T, et al. High-dose therapy followed by stem cell transplantation in Hodgkin’s lymphoma: past and future. Expert Rev Hematol. 2013;6(4):451–64.

Article  PubMed  CAS  Google Scholar 

Anderson CC, Goldstone AH, Souhami RL, Linch DC, Harper PG, McLennan KA, et al. Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma. Cancer Chemother Pharmacol. 1986;16:170–5.

Article  PubMed  CAS  Google Scholar 

Till BG, Madtes DK. BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma. 2012;53(6):1019–20.

Article  PubMed  Google Scholar 

Olivieri J, Mosna F, Pelosini M, Fama A, Rattotti S, Giannoccaro M, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transplant. 2018;24(9):1814–22.

Article  PubMed  Google Scholar 

Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365(18):1653–5.

Article  PubMed  CAS  Google Scholar 

Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14(1):309–17.

Article  PubMed  CAS  Google Scholar 

Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26(2):204–10.

Article  PubMed  CAS  Google Scholar 

Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin’s lymphoma: a practice guide for patient management. Oncologist. 2013;18(8):954–64.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17(4):1244.

Article  PubMed  CAS  Google Scholar 

Pavlů J, Auner HW, Ellis S, Szydlo RM, Giles C, Contento A, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B‑cell lymphoma: treatment outcome and risk factor analysis from a single centre. Hematol Oncol. 2011;29(2):75–80.

Article  PubMed  Google Scholar 

Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95.

Article  PubMed  CAS  Google Scholar 

Stahl W, Eisenbrand G. Comparative study on the influence of two 2‑chloroethylnitrosoureas with different carbamoylating potential towards glutathione and glutathione related enzymes in different organs of the rat. Free Radic Res Commun. 1991;14(4):271–8.

Article  PubMed  CAS  Google Scholar 

AlJohani NI, Nasani M, Ahmed HE, Rehman JU, Nawaz A, Alzahrani Z, Albeirouti B. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Stem Cell Ther. 2021;14(4):327–35.

Article  CAS  Google Scholar 

Dikshit N, Sinha R, Maity H, et al. Dose escalation study of bendamustine based conditioning regime (Bace-bendamustine, cytarabine,cyclophosphamide and etoposide) in patients with lymphoma undergoing autologous stem cell transplant. Hematol Transfus Int J. 2017;5(5):294–7.

Google Scholar 

Garciaz S, Coso D, Schiano de Collela JM, Broussais F, Stoppa AM, Aurran T, et al. Bendamustine-based conditioning for non- 447 Hodgkin lymphoma autologous transplantation: an increasing 448 risk of renal toxicity. Bone Marrow Transplant. 2016;51:319–21.

Article  PubMed  CAS  Google Scholar 

Gupta A, Gokarn, Anant, Rajamanickam, Deepan, Punatar S, Thippeswamy R, Libin M, Bagal, Bhausaheb, Kannan, Sadhana, Khattry N. Lomustine, cytarabine, cyclophosphamide, etoposide—An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. J Can Res Ther. 2018;14(5):926–33. https://doi.org/10.4103/0973-1482.181183.

Article  CAS  Google Scholar